of these interventions have been tried in patients but the results have been disappointing. Although several agents, including metoprolol, 6 cyclosporine, 7, 8 atrial natriuretic peptide, 9 and exenatide, 10 show promise in early clinical trials, to date, there is no accepted method to reduce infarct size in the clinical arena beyond timely reperfusion. 5 
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Although there are several reasons to explain such failures, 11, 12 probably the most important is that many preclinical studies have lacked sufficient rigor. 5 For example, in most studies published to date, animals have not been randomized, investigators have not been blinded, exclusion criteria and sample sizes have not been established a priori, and details of protocols (which may impact outcome) have not been thoroughly standardized. Not surprisingly, the results have frequently not been reproducible from one laboratory to another. 5 If a therapy is not reproducibly effective in the experimental setting, it is unlikely that it will be effective in the much more complex clinical setting, in which a large number of confounding variables affect the results. 5, 13, 14 The need for a new strategy is obvious. 5, [15] [16] [17] [18] Given that the approach used in the past 40 years has failed to produce a single therapy that is approved for infarct size reduction in humans, it seems implausible that continuing with this same failed approach will be fruitful.
Accordingly, we adopted a new paradigm by establishing a functional consortium (Consortium for preclinicAl assESsment of cARdioprotective therapies [CAESAR] ), 19 analogous to a multicenter, randomized clinical trial, in which promising therapies are subjected to a rigorous test of efficacy and reproducibility with respect to infarct size reduction ( Figure 1 ). Our rationale is that therapies that survive the CAESAR test have the best chance of clinical success and should be considered for human studies. This approach represents a dramatic departure from the modus operandi of the past 40 years. Performing preclinical studies with the rigor of multicenter, randomized clinical trials has rarely, if ever, been done in basic research, particularly in studies of cardioprotection, and thus constitutes a veritable paradigm shift for the field. The National Institutes of Health Director, Dr Francis Collins, recently lamented the lack of reproducibility of scientific work and effectively issued a call to action. 20 The goal of CAESAR is to serve as a public resource for the rigorous assessment of candidate infarct-sparing drugs; however, before CAESAR can be used to screen cardioprotective therapies, it is necessary to validate it by testing the ability of the consortium to (1) detect cardioprotection in all 3 species used (mice, rabbits, and pigs) and (2) generate results that are comparable and reproducible between 2 different centers that use the same protocol without knowledge of each other's data. For these essential validation studies, we selected ischemic preconditioning (IPC), 21 which activates the largest number of protective pathways and is the most robust and reproducible cardioprotective intervention known to date. Here, we report the development and validation of CAESAR and our initial experience with this novel approach to preclinical investigation. Perhaps more importantly, we provide detailed protocols for testing potential infarct-sparing therapies in mice, rabbits, and pigs; these protocols, which are based on extensive studies and thoughtful discussions among CAESAR investigators and the Protocol Review and Monitoring Committee, should be useful to many investigators working in the field of cardioprotection.
Methods
One of the main goals of CAESAR was to develop protocols that enable rigorous assessment of potential infarct-sparing therapies in mice, rabbits, and pigs. To make these protocols available to the entire Center has access to data before a study being reported to the Protocol Review and Monitoring Committee (composed of cardioprotection experts from non-CAESAR member institutions). February 13, 2015
scientific community and to facilitate their use by others, the protocols are described herein in great detail. All studies were approved by the Animal Care and Use Committees of the component Universities of CAESAR and were performed in accordance with the Guide for the Care and Use of Laboratory Animals (DHHS Publication No. [National Institutes of Health] 86-23). Ultimately, both Centers for each species used the same Animal Care and Use Committee protocol. In addition, a group of extramural scientists serve on the Protocol Review and Monitoring Committee (PRMC; Figure 1 ).
Mouse Model of Myocardial Ischemia/Reperfusion Injury
Male Institute of Cancer Research mice were obtained from Harlan Laboratories (Houston, TX) and housed under specific pathogen-free conditions in a room (22°C-24°C temperature; 55%-65% relative humidity; and a 12:12-h light-dark cycle). The mouse diet was Rodent Diet 5010 (www.LabDiet.com). At approximately 13 weeks and 42 g of body weight, mice were premedicated with atropine sulfate (0.04 mg/kg IM) and anesthetized 5 minutes later with pentobarbital sodium (60 mg/kg IP). Additional doses of pentobarbital (5 mg/kg, IP) were given during the protocol as needed to maintain anesthesia, which was determined by the presence of the toe pinch reflex and leg movements during the procedures. The animals were placed in a supine position with the paws taped to the operating table. Surface leads were placed subcutaneously to obtain the ECG, which was recorded throughout the experiments. Before surgery started, mice were given gentamicin (0.7 mg/kg IM).
A midline cervical skin incision was performed, and the muscles overlying the trachea were retracted to allow visualization of the endotracheal tube (PE-60 tubing) as it was placed in the trachea. To facilitate intubation, a rubber band was placed behind the upper incisors and fastened to the operating table so that the neck was slightly extended. To place the endotracheal tube, the tongue was slightly retracted, and the beveled end of the tube (which was marked with a black marker) was inserted through the larynx and into the trachea with care taken not to puncture the trachea or other structures in the pharyngeal region. The tube was advanced 8 to 10 mm from the larynx and taped in place to prevent dislodgment. The animals were ventilated with room air supplemented with oxygen (1 L/min) at a rate of 105 breaths/min and with a tidal volume of 10.3 μL/g using a mouse ventilator (MiniVent 845, Hugo Sachs Elektronik-Harvard Apparatus, Germany). The endotracheal tube was inserted loosely into the tube connected to the ventilator to avoid lung overexpansion. To prevent blood pressure drops because of artificial ventilation, the loss of negative intrathoracic pressure during the open-chest state, and blood losses, blood from a donor mouse was given intravenously at a dose of 20 mL/kg (≈0.5 mL/mouse) divided into 3 equal boluses (first bolus, after the endotracheal tube was connected to the ventilator; second bolus, after the chest was opened; third bolus, after the chest was closed). 22 Body temperature was carefully monitored with a rectal probe connected to a digital thermometer (Cole-Parmer Instrument, Vernon Hill, IL) and was strictly maintained between 36.7°C and 37.3°C throughout the experiment using an external heating system (ie, heating pad and lamps).
Aseptic techniques were used for surgery, which was performed in a dedicated clean room. With the aid of a dissecting microscope or surgical loupes (Care Optical Industrial Co, Ltd, China) and a microcoagulator (ASSI Polar-Mate Isolator, San Diego, CA), the chest was opened through a midline sternotomy. An 8-0 nylon suture was passed with a tapered needle under the left coronary artery 2 to 3 mm from the tip of the left auricle, and an atraumatic balloon occluder was applied on the artery and inflated to occlude the artery. Successful performance of coronary occlusion and reperfusion was verified by visual inspection (ie, by noting the development of a pale color in the distal myocardium on inflation of the balloon and the return of a bright red color because of hyperemia after deflation), observing ST-segment elevation and widening of the QRS on the ECG during ischemia and their resolution after reperfusion. After the coronary occlusion-reperfusion protocol was completed, the chest was closed in layers, and a small catheter was left in the thorax for 10 to 20 minutes to evacuate air and fluids. The mice were removed from the ventilator, kept warm, given fluids (1.0-1.5 mL of 5% dextrose in water intraperitoneally), and allowed 100% oxygen via nasal cone (or the mouse cage was kept in an oxygen tent). A ≈70-μL blood sample was obtained from the tail vein at 2 hours of reperfusion for measurement of the cardiospecific injury marker, cardiac troponin I (cTnI). We have found that plasma cTnI levels peak at 2 hours in this model, and that the 2-hour values of cTnI correlate well with pathologist-based measurements of infarct size.
For analgesia, we administered buprenorphine (0.1 mg/kg SC right after closing the chest) and ketoprofen (5 mg/kg IM once a day for 48 hours, starting immediately after closing the chest). After surgery, mice were observed every hour for the first 6 hours. Animals were placed in cages with heating pads in an enriched oxygen tent for at least 24 hours.
Ischemic Preconditioning
IPC was produced with a sequence of 6 cycles of 4-minute coronary occlusion and 4-minute reperfusion ( Figure 2A ). This protocol was selected because it is highly effective in inducing early and late PC in mice. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Myocardial infarction (ie, index ischemia) was produced by a 30-minute coronary occlusion followed by 48 hours of reperfusion. A 30-minute occlusion was selected because in our previous studies it produced infarcts averaging 50% of the region at risk (RR) in control animals, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] which enabled us to detect either a detrimental or a beneficial effect of the intervention examined. Mice were subjected to either IPC or sham IPC.
At the conclusion of the study, mice were given heparin (1 U/g IP), after which they were anesthetized with pentobarbital sodium (60 mg/kg IP) and euthanized with an intravenous bolus of KCl. The heart was excised and perfused with Krebs-Henseleit solution through an aortic cannula (22-or 23-gauge needle) using a Langendorff apparatus. To delineate infarcted from viable myocardium, the heart was then perfused with a 1% solution of 2,3,5-triphenyltetrazolium chloride in phosphate buffer (pH 7.4, 37°C) at a pressure of 60 mm Hg (≈3 mL for >3 minutes). To delineate the ischemic zone, the coronary artery was then tied at the site of the previous occlusion and the aortic root was perfused with a 5% solution of phthalo blue dye (Heucotech, Fairless Hill, PA) in normal saline (2 mL for >3 minutes). As a result of this procedure, the portion of the left ventricle (LV) supplied by the previously occluded coronary artery (RR) was identified by the absence of blue dye, whereas the rest of the LV was stained dark blue. 22 All atrial and right ventricular tissues were excised, and the heart was frozen in a −20°C freezer. The LV was cut into 5 to 7 transverse slices, which were fixed in 10% neutral buffered formaldehyde, weighed, and photographed. The images were uploaded to the secure CAESAR data site, and fixed heart sections were sent to the CAESAR Pathology Core to measure infarct size.
Exclusion Criteria
Mice with major technical problems including failure of intubation, severe bleeding, lung damage, coronary artery damage, or balloon malfunction; any signs of hypoxia or hypotension before the ischemia/reperfusion injury procedures; outside the weight range of 32 to 48 g; outside the age range of 12 to 15 weeks; or with a RR <20% of LV weight were excluded from the final analysis.
Rabbit Model of Myocardial Ischemia/Reperfusion Injury
Pathogen-free, healthy, New Zealand White male rabbits were used at ≈90 days and 2.2 kg of body weight. After establishment of a venous access by placement of a butterfly needle catheter (23G×¾″) on a marginal ear vein, rabbits were anesthetized with sodium pentobarbital (0.5 mL of 5% solution IV), intubated with an endotracheal tube, and mechanically ventilated with air enriched with oxygen. The ventilation rate was maintained between 28 and 30 breaths/min. Anesthesia was maintained with sodium pentobarbital (total dose, 35 mg/kg IV). Body temperature was monitored continuously with a rectal probe attached to a thermocouple. A heating blanket was used to maintain body temperature between 36.0°C and 39.0°C. The rabbits were shaved, and the surgical area was washed 3× with isopropyl alcohol. Betadine was applied with sterile gauze to the surgical area and allowed to dry. A transparent, sterile, adhesive drape (3 mol/L) was used as a barrier on the surgical site. Under sterile conditions, the heart was exposed through a left thoracotomy in the fourth intercostal space. After opening the pericardium, a 3-0 tapered needle silk suture was passed beneath a major branch of the left coronary artery perpendicularly to the vessel. Lifting the suture against a cotton-tip applicator performed a brief test of coronary occlusion to estimate the size of the RR. The site of the balloon inflation was chosen in an effort to obtain a risk area of ≈25% (not <15% nor >35%) of the LV. A balloon occluder (fashioned from 18-gauge Tygon tubing) was placed along the top of the coronary artery and secured with 3-0 silk on the anterior LV wall. A piece of aluminum sheet (0.2-0.3-mm thick) was placed on top of the balloon as a backing material for holding a silk suture knot and for aligning the balloon occluder parallel to the coronary artery. Careful placement of the balloon is critical for a later successful conscious study, that is, the suture knot should be neither too tight (which would cause blood flow restriction after balloon deflation) nor too loose (which would fail to induce complete coronary occlusion during balloon inflation). After balloon placement, a brief test (10-s balloon inflation) was performed, and proper function of the occluder was confirmed by observing cyanosis of the distal myocardium on inflation of the balloon and hyperemia after deflation. The tail of the balloon was anchored to the surface of the LV wall with a 6-0 suture to avoid twisting of the balloon occluder. A small piece of plastic film (≈0.1-mm thick) was placed between the surface of the LV wall and the balloon occluder to help distribute pressure evenly on the top of the coronary artery during balloon inflation. A bipolar lead was anchored to the chest wall to record the ECG. The wires and the occluder tubing were tunneled under the skin and exteriorized through small incisions between the scapulae. The chest wound was closed in layers, and a small tube was left in the thorax for 3 days to evacuate air and fluids. After surgery, rabbits recovered in a dedicated recovery area where they received supplemental oxygen and were kept warm. Buprenorphine (0.1 mg/kg IM) was administered preoperatively for pain and repeated every 12 hours for the first 48 hours postoperatively. Cefazolin (15 mg/kg SC) was administered preoperatively and repeated every 24 hours for the first 48 hours postoperatively. Rabbits were allowed to recover for a minimum of 7 days after surgery.
Throughout the coronary occlusion-reperfusion sequence, rabbits were kept in a cage in a quiet, dimly lit room. A venous line was established by placing a 24-gauge angiocatheter on a marginal ear vein for blood sample draw and for medication. Under local anesthesia (benzocaine spray), the ear dorsal artery was cannulated with a 22-gauge angiocatheter to monitor arterial pressure. Arterial pressure and ECG were continuously recorded. Rabbits received ketoprofen (3.0 mg/kg SC) 2 hours before and diazepam (4 mg/kg IP) 20 minutes before the onset of ischemia; in addition, they received heparin (50 U/kg IV) before occlusion to prevent coronary arterial thrombosis. All rabbits were subjected to a 45-minute coronary artery occlusion and 3 days of reperfusion by inflating/deflating the hydraulic balloon occluder. The performance of successful coronary occlusions was verified by observing the development of ST-segment elevation and changes in the QRS complex on the ECG. Rabbits that were assigned to the IPC group received three 5-minute coronary occlusions interspersed with 10 minutes of reperfusion before the 45-minute coronary occlusion ( Figure 2B ). When ventricular fibrillation occurred, defibrillation was performed immediately (50 J) by placing a pediatric defibrillation paddle on both sides of chest. Serial 0.4-mL blood samples were collected at baseline and 1, 2, 4, 24, and 48 hours after reperfusion for measurement of cTnI (both peak levels and area under the curve).
At the end of the experiment, rabbits were given heparin (100 U/kg IV), after which they were anesthetized with pentobarbital (50 mg/kg IV) and euthanized with KCl. The heart was quickly mounted onto a Langendorff apparatus. The aortic root was perfused with Krebs-Henseleit solution (≈30 mL; 37°C) at a pressure of ≈60 mm Hg to remove all blood. The coronary artery was then tied at the site of the previous occlusion, and the aortic root was perfused with a 5% solution of phthalo blue dye in normal saline (≈10 mL for >3 minutes). The heart was cut into 5 to 6 transverse slices (each ≈2-mm-thick), which were incubated for 15 minutes at 37°C in a 1% solution of triphenyltetrazolium chloride in phosphate buffer (pH 7.4) to delineate infarcted from viable myocardium. The heart slices were fixed in 10% neutral buffered formaldehyde for 4 to 24 hours with a weight on top to keep the heart slice flat for the initial 30 minutes. The atrial and right ventricular tissue were removed, and the LV slices were numbered from apex to base as 1 through 5 or 6, weighed, and photographed on both sides of the slices together with a ruler. The images together with the tissue slice weight information were uploaded to the secure CAESAR data site for measurement of the sizes of the nonischemic, ischemic/reperfused, and infarcted areas. After photographs were taken, each slice was placed in the cassette for paraffin embedding. All formalin-fixed tissue sections were sent to the Infarct Size Core for histology assessment. The images and tissue slice weight information were uploaded to the appropriate folder on the secure, CAESAR data site. The Pathology Core subsequently accessed these files for measurement of the sizes of the nonischemic, ischemic, and infarcted areas.
Exclusion Criteria
Rabbits with major technical problems, including failure of intubation, severe bleeding, lung damage, coronary artery damage, or occluder malfunction; any signs of hypoxia or hypotension before the ischemia/reperfusion injury procedures; outside the 2.5 to 3.0 kg weight range; or with a RR<20% of LV weight, were excluded from the final analysis.
Pig Model of Myocardial Ischemia/Reperfusion Injury
Experimental myocardial infarction was performed at ≈90-day-old female Yorkshire pigs weighing 30 to 45 kg (Palmetto Research Swine, Reevesville, SC). The animals were acclimated for 7 to 10 days after arrival and maintained on Laboratory Diet 5084 (Cincinnati Laboratory Supply). Pigs were assigned randomly to the control or IPC group and fasted for ≥12 hours before sedation for the closed-chest myocardial infarct procedure. On the day of the coronary artery occlusion, the pigs were sedated using a cocktail of ketamine hydrochloride (20 mg/kg IM) and xylazine (2 mg/kg IM). After adequate sedation (≈15 minutes), they were moved to the preoperative care room. An intravenous catheter was placed in a marginal ear vein for the administration of fluids and drugs. Diazepam (1 mg/kg IV) was administered to allow for endotracheal intubation. An appropriately sized endotracheal tube was inserted for mechanical ventilation. The chest and groin were shaved and prepared for cardiac catheterization procedure. The pig was then moved to the catheterization suite and placed on the operating table in the lateral position with the right side up. Body temperature was maintained at 36.5°C to 39.0°C during the procedure with a water blanket and hot air veterinary blanket. Aspirin (300 mg IV) and ceftiofur (3 mg/ kg SC) were administered, and the pig was ventilated with 50/50 oxygen/room air or nitrogen at initial settings of 10 to 20 breaths/ min and 10 to 12 mL/kg tidal volume. Another ear vein catheter was placed for infusion of methohexital sodium (10 mg/kg/h IV). Surface ECG leads (limb lead II) were placed and connected to a patient monitor for continuous electrocardiographic data. To induce a stable anesthetic plane, methohexital sodium infusion was initiated once the pig was on ventilation. Methohexital sodium dosing was adjusted between 5.5 and 12.0 mg/kg per hour throughout the experimental procedures, and actual dosing varied slightly based on the anesthetic state of each animal. Animals were monitored continuously to confirm adequate anesthesia.
The groin and right neck were scrubbed with chlorhexidine-based surgical disinfectant scrub, followed by alcohol-soaked gauze in a series of 3 cycles. Then, povidone-iodine solution was sprayed on the surgical sites. The animal was fitted with sterile drapes, and sterile instruments were handed off to the surgeon. All surgical procedures were performed using standard sterile technique, including sterile gowns, gloves, masks, and instruments. Arterial blood gases were measured routinely to ensure physiological stability. Ventilation rates were adjusted to maintain PCO 2 between 35 and 45 mm Hg, PO 2 between 100 and 200 mm Hg, and pH between 7.35 and 7.45. If metabolic acidosis (low pH with HCO 3 deficit) occurred, sodium bicarbonate was given according to the formula: sodium bicarbonate (mEq) required=0.3×body weight (kg)×base deficit (mEq/L). A cut-down (local lidocaine injection) on the right side of the neck was performed, and the right jugular was used for placement of a 7 to 9 F Chronic-Cath polyurethane catheter (Access Technologies). This catheter was implanted, secured, and tunneled to the back of the neck for serial blood withdrawals at the postoperative time points. The catheter dead space was filled with heparin (1000 U/mL) after each withdrawal to maintain patency; care was taken to fill the dead space only with no spillover into the systemic circulation.
After the jugular catheter was placed, the pig was moved to its supine position. External defibrillator pads were placed, fixed on the pig's chest skin, and connected to a hands-free defibrillator. Through a right femoral artery cut-down, a 7 to 8 F fast-cath sheath was introduced so that a 6 to 7 F Hockey-stick guide catheter could be advanced to the heart for the angiogram and balloon placement. A left femoral cut-down was performed, and a 6 to 7 F fast-cath sheath was introduced and used for a 5 to 6 F pigtail catheter that was advanced to the LV and used to inject microspheres. Arterial blood pressure was measured from the side arm of the right arterial sheath, which was connected to a fluid filled pressure transducer. Heparin (300 U/ kg IV) was given to prevent clotting of the sheaths and catheters during the procedure.
A 6 to 7 F Hockey-stick catheter over a 0.038″ guidewire was fluoroscopically guided to the left main coronary ostium. A bolus of contrast dye was injected to obtain a coronary cineangiogram for determining the site of balloon placement and the size of the balloon catheter. After angiographic measurement of the mid-left anterior descending coronary artery (LAD) diameter at the site to be occluded, a 0.014″ guidewire was advanced into the distal LAD and an appropriately sized (2.5-3.5 mm) balloon-tipped angioplasty catheter was telescoped over the wire and positioned in the mid-LAD distal to the second diagonal terminal branch (when the second diagonal branch was too distal, a first diagonal target was attempted). Placement of the balloon was verified by intracoronary contrast dye injection and documented by cineangiogram before inflation. The goal was to occlude the LAD coronary artery just distal to the second diagonal branch, producing a RR ≈25% to 30% of the LV mass. If the RR (measured postmortem) was <20% of the LV, the animal was excluded. This RR is distributed primarily in the anterior free wall but includes a portion of the anterior septum.
After the instrumentation described above, baseline hemodynamics were collected and microspheres (samarium [Sa], isotope 1) were given after stabilization. After baseline hemodynamics and microsphere injection, a prophylactic dose of amiodarone (4 mg/kg IV) was administered slowly to reduce arrhythmias. At reperfusion, amiodarone was infused at a rate of 2.4 mg/kg per hour (0.04 mg/kg per minute IV) until 15 minutes into reperfusion. A lidocaine bolus (2 mg/kg IV) was also given, followed by a lidocaine infusion at a rate of 3.0 mg/kg per hour (0.05 mg/kg per minute).
Pigs were randomly assigned to a control or an IPC group ( Figure 2C ). In control pigs, the LAD occlusion was maintained for 60 minutes (index ischemia) followed by reperfusion, targeting an infarct size of ≈60% of the RR. In pigs undergoing IPC, three 5-minute LAD occlusion/10-minute reperfusion cycles were performed before the 60-minute index ischemia. To achieve LAD occlusion, the angioplasty balloon was inflated at 8 to 10 Atm. After balloon inflation, a cineangiogram was obtained with contrast injection through the hockey-stick guiding catheter to confirm the balloon position and complete occlusion of the distal LAD. Both the inflation and the position of the balloon were confirmed by contrast angiogram again at the end of ischemia. When ventricular fibrillation occurred, defibrillation was immediately performed through the fixed skin electrodes using a 360 joules DC shock. At 45 minutes into occlusion, a second injection of microspheres (europium [Eu], isotope 2) was given to quantify collateral blood flow to the RR, which is used as a covariate of infarct size. After the 60-minute ischemic period, the intracoronary balloon was deflated to initiate reperfusion and the balloon catheter was withdrawn. After balloon withdrawal, an additional cineangiogram was made to verify vessel patency. A third injection of microspheres (lutetium [Lu], isotope 3) was given at 15 minutes of reperfusion to confirm vessel patency and early reperfusion. Hemodynamic data were collected at 15 and 45 minutes of ischemia and at 15 and 60 minutes of reperfusion.
Buprenorphine (0.025 mg/kg IM) was given for postprocedural analgesia at 15 minutes into reperfusion and a transdermal fentanyl patch (2.5 μg/kg per hour) was placed at the end of the procedure for the 72-hour follow-up. The femoral catheters were removed, and the groin access sites were closed in layers using 3-0 Vicryl for internal sutures and 3-0 polydioxanone suture for the final subcutaneous layer. After hemodynamic readings were recorded through 60 minutes of reperfusion, pigs were weaned from anesthesia and moved to a postoperative care area when spontaneous breathing and hemodynamic stability were achieved. A pulse oximeter probe was placed on the ear or tail to measure oxygen saturation. Extubation was performed when the pig began to chew and exhibited a gag reflex. Pigs were monitored until they righted themselves without assistance. Ceftiofur (3 mg/kg SC) was repeated on postoperative days 1 and 2. Blood samples (1 mL) were collected from the jugular venous catheter at 2, 4, 6, 24, and 48 hours of reperfusion for cTnI assays.
At 72 hours of reperfusion, the pig was sedated using a cocktail of ketamine hydrochloride (20 mg/kg IM) and xylazine (2 mg/kg IM). After adequate sedation (≈15 minutes), the pig was moved to the preoperative care room, received propofol (1.5 mg/kg IV) via the indwelling venous catheter before intubation and was intubated with an appropriately sized endotracheal tube. For final data collection, the pig was then transported to the catheterization laboratory, where it was placed on a heating blanket to maintain rectal temperature at 36.5°C to 39.0°C. The pig was ventilated on 50/50 oxygen/nitrogen mixtures at 10 to 12 breaths/min and 10 to 12 mL/kg tidal volume. General anesthesia was maintained with isoflurane (1.0%-1.5%). Surface ECG leads (limb lead II) were placed to record electrocardiographic data. Through a right carotid artery cut-down, a 7 to 8 F sheath was placed and a pressure transducer was connected to the side port of the sheath to record arterial pressure. A 5 to 6 F pigtail catheter with infusion lumen was guided into the LV for injection of the 72-hour microsphere injection (Lanthanum [La], isotope 4). After the final microsphere injection, the pig was heparinized (100 U/kg IV) and deeply anesthetized with 5% isoflurane. A bolus of 3 to 6 mL/ kg of 3 mol/L KCl solution was injected to the LV cavity via the pigtail catheter until the heart was completely arrested. Asystole was confirmed by cessation of cardiac electric activity from ECG monitoring. After cessation of vital signs, the heart was harvested for postmortem perfusion.
The heart was mounted onto a dual perfusion system. The LAD was cannulated at the site of the previous occlusion to perfuse the ischemic/reperfused myocardium (referred to as the RR), whereas the aortic root was cannulated to perfuse the nonischemic myocardium retrogradely. After perfusion with Krebs-Henseleit solution at 37°C (to remove any blood), the LAD cannula was perfused with a 1% (wt/vol) 2,3,5-triphenyltetrazolium chloride (TTC) solution in phosphate buffered saline at 37°C and the aortic cannula with a 5% (v/v) solution of phthalo blue dye in normal saline. The pressure was maintained at ≈80 mm Hg in both cannulas. After perfusion for ≈15 minutes when a deep red in the epicardial surface of the risk zone was seen, the perfusion was stopped. The heart was then sectioned from apex to base into 6 to 7 transverse slices, each ≈1-cm thick, until no RR tissue was noted. The LV slices were fixed in 10% neutral buffered formaldehyde for 4 to 24 hours. This dual perfusion stains the nonischemic myocardium dark blue, the surviving tissue (TTCpositive region) brick red, and the infarcted tissue (TTC-negative region) pale tan/yellow. After formalin fixation, the atrial and right ventricular tissue were removed, the LV slices were numbered from apex to base as 1 through 6 (or 7, if applicable), weighed, and photographed on both sides of the slices together with a ruler. After photographs were taken, formalin-fixed tissue was sent to the Pathology Core for infarct size/histology assessment. The images and tissue slice weight information were uploaded to the appropriate folder on the secure CAESAR data site. The Pathology Core subsequently
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Measurement of Regional Myocardial Blood Flow Using Microspheres
For measurement of regional myocardial blood flow (RMBF), biopal stable-isotope neutron-activated microspheres (15±5 μm; BioPhysics Assay Laboratory, Inc, Worcester, MA) were used as described. 33 As mentioned above, microspheres were injected at 4 time points: baseline, during coronary occlusion (15 minutes before reperfusion), 15 minutes after reperfusion, and 72 hours after reperfusion. At each time point, a total of 5×10 6 microspheres (2 mL) labeled with samarium (Sa), europium (Eu), lutetium (Lu), or lanthanum (La) were injected >30 s into the LV cavity through the pigtail catheter, while a reference blood sample was simultaneously drawn from the side arm of the arterial sheath catheter for calculation of absolute myocardial blood flow using a withdrawal pump at 7 mL/min for 90 s.
After the LV sections were photographed and weighed, 4 transmural tissue blocks (≈1 g) were obtained from both the ischemic/ reperfused and the nonischemic regions (to avoid admixture of ischemic and nonischemic tissue, ischemic specimens were obtained ≥1 cm inside the boundaries of the occluded bed). Each specimen was divided into endocardial and epicardial halves, rinsed in a salinefree buffer, placed in tissue sample vials, and weighed. Tissue and reference blood samples were processed according to BioPAL's General Protocol For Blood Flow Experiments and were sent to BioPAL for the analysis, which uses neutron activation technology for the measurement of microsphere content. 33 Absolute RMBF was computed in each sample with the formula: RMBF=(counts in tissue sample×reference blood sample withdrawal rate)/(counts in reference blood sample×tissue weight in gram) and expressed as mL/ min per gram. These data were uploaded to the appropriate folder on the secure CAESAR data site for statistical analysis by the Data Coordinating Center (DCC).
Exclusion Criteria
The following events represented grounds for excluding a pig from the study: (1) body weight outside of the range of 30 to 45 kg; (2) body temperature outside of the range (36.5-39.0°C); (3) dose of anesthetic during ischemia outside of the range (7.0-8.0 mg/kg per hour); (4) RR<20% of LV; (5) RMBF during ischemia >8.0% of the nonischemic zone RMBF; (6) absence of RMBF data during ischemia; (7) average heart rate during ischemia (average of all ischemic time points in a given animal) outside the range of 60 to 120 bpm; (8) average mean arterial pressure during ischemia (average of all ischemic time points in a given animal) outside the range of 50 to 110 mm Hg; (9) a total of 15 unsuccessful electric shocks delivered during ventricular fibrillation failing to convert to normal sinus rhythm.
Image Analysis for Infarct Size Determination
In all 3 species (mice, rabbits, and pigs), infarct size determination was performed from the image files. With our protocol, the nonischemic myocardium is blue, the viable tissue within the ischemic zone is red, and the infarct is white, tannish, yellow, or brown, depending on whether there was hemorrhage and depending on how much organization of the infarct had occurred. For analysis, Photoshop was used to delineate the area of the entire LV slice; then the blue nonischemic tissue was erased to generate an image that included only the RR, and then the red viable myocardium was erased to generate an image that included only the infarct. These images were then analyzed using ImageJ to determine the number of pixels in each image, following which we calculated, for each image, the RR as a percentage of the LV and the infarct as a percentage of the LV. The data were entered into a spreadsheet that included the slice weight. For each slice, the mean value for infarct size and RR was determined by averaging the data for the apical and basal surfaces and by multiplying the average by the slice weight to calculate the amount of infarct, viable-ischemic tissue, and nonischemic tissue. The weights from each slice were added to determine the overall amount of infarct and RR. At the end of the analysis, the spreadsheet was reviewed along with the corresponding histology to validate the data and eliminate data entry errors.
To confirm the results obtained with TTC staining and resolve any ambiguous situations, hematoxylin and eosin-stained sections were examined by light microscopy and correlated with the TTC images. The histology sections were from the center of the slice, whereas the TTC images were from both the apical and the basal surfaces of the slice, so there was not a perfect match, but the histology was used to guide the analysis. Completed spreadsheets with data for individual slices and total values were then uploaded to the CAESAR data site, without the knowledge of the experimental protocol for individual hearts. All of the images generated by Photoshop were saved on the server so that any discrepancies between the Core analysis and analysis by the animal Centers could be investigated by comparison of the images, which was only done post hoc.
cTnI Release
For all species, blood was collected in heparinized tubes and centrifuged to separate plasma. For mice, a ≈70-μL blood sample was obtained from the tail vein at 2 hours of reperfusion because we have found that cTnI levels peak at this time in this model. Moreover, the 2-hour values of cTnI correlate well with TTC-based measurements of infarct size. For rabbits, serial blood samples (≈0.4 mL) were obtained from the ear vein at baseline and 1, 2, 4, 24, and 48 hours of reperfusion. For pigs, serial blood samples (≈1.0 mL) were obtained at baseline and 2, 4, 6, 24, and 48 hours of reperfusion. Plasma cTnI levels were measured with species-specific cTnI ELISA kits according to the manufacturer's instructions (Life Diagnostics, West Chester, PA). Each assay was performed in duplicate without the knowledge of the treatment group. All of the final cTnI results (ng/mL) were submitted to the DCC via the CAESAR ShareFile site for statistical analysis.
End Points for Each Species
The primary end point for the murine model was infarct size (expressed as a fraction of the RR [infarct/RR]); the secondary end points were age (in weeks), body weight (g), and heart rate (bpm) at each time point (baseline, 5-, 15-, and 30-minute occlusion and 5 and 15-minute reperfusion), body temperature (°C) at each time point (baseline, 5-, 15-, and 30-minute occlusion, and 5-and 15-minute reperfusion), heart weight (mg), LV weight (mg), RR (mg), infarct size (mg), RR per LV (RR/LV), infarct size per LV (infarct/LV), cTnl levels at baseline, and the cTnI plasma level at 2 hours of reperfusion.
In rabbits, the primary end point was infarct size (expressed as a fraction of the RR [infarct/RR]); the secondary end points were age (in days), body weight (kg), heart rate (bpm) at each time point (baseline, 15-, 30-, and 45-minute occlusion, and 15-minute reperfusion), heart weight (g), LV weight (g), RR (g), infarct (g), RR (% of LV), infarct (% of LV), cTnI (ng/mL) at each time point (0, 1, 2, 4, 24, and 48 hours since reperfusion), and the cumulative cTnI release (ng/mL).
For pigs, the primary end point was infarct size (expressed as a fraction of the RR [infarct/RR]); the secondary end points were age (in days), body weight (kg), number of defibrillations, heart rate (bpm), and mean arterial pressure (mm Hg) at each time point (baseline, 15-, and 45-minute occlusion, and 15-minute and 72-hour reperfusion), heart weight (g), LV weight (g), RR (g), infarct (g), RR (% of LV), infarct (% of LV), cTnI (ng/mL) at each time point (0, 2, 4, 6, 24, and 48 hours of reperfusion), the cumulative cTnI release (ng/ mL), and RMBF at 4 time points (baseline, occlusion, 15 minutes, and 72 hours of reperfusion).
Statistical Analyses
This study was designed to determine whether IPC reduces infarct size in each of the 3 species (mouse, rabbit, and pig), and whether the results from 2 laboratories using the same animal protocol were reproducible. The sample size was calculated and decided a priori (ie, before the start of the experiments) to detect a 20% (for mice and rabbits) or a 25% (for pigs) reduction in infarct size normalized to the RR (infarct/RR) in the IPC groups, with a power 80% and a 2-sided 5% Type I error rate 34 (eg, if infarct size was 50% of the RR in control pigs, the sample size would enable us to detect a reduction of infarct size to 25% of the RR in the IPC group with a power of 80% and a 2-sided 5% type I error rate). The required number of animals was adjusted to account for 20% attrition because of mortality and exclusions based on the investigators' recent experience.
The animals from each laboratory were assigned to IPC or control groups using a blocked randomization scheme to ensure that the assignment was randomized and balanced. 34 The Pathology and Biomarker Cores measured infarct size and cTnl levels, respectively, while being blinded to the treatment group. Animal characteristics (eg, age, weight, heart rate, and body temperature) were measured in each animal at each center, according to the protocol. The DCC's statistician (Dr Kong) analyzed the data for significant differences.
To examine whether IPC produced a significant infarct size reduction in each laboratory, and to examine whether the control groups in the 2 laboratories that used the same model were similar, 2-way ANOVA with t tests was used. 35 Secondary end points were also analyzed using 2-way ANOVA in the same fashion as the primary end point. The summarized mean and SD for each end point for each laboratory and each treatment group, along with the P values to test whether the IPC and control groups from each laboratory were significantly different, the P values for comparing the control groups from the 2 laboratories, and the P values for comparing the IPC groups from the 2 laboratories, are reported. A test was considered significant if the P value was <0.05. The correlation between the histological measurements of infarct size and cTnI levels was assessed by linear regression, Pearson correlation coefficients, and graphical data analyses.
Results

Overview
The goal of this first phase of CAESAR was to initiate the operations of the Consortium, to address logistical issues, to refine the protocols, to validate the work of the Consortium by demonstrating its ability to detect the protective effects of IPC, and to verify the reproducibility of the work between centers. We worked diligently to reconcile technical aspects of the surgical models between centers and to optimize the sample and data flow through the various cores. Using 2 methods to assess myocardial injury (TTC staining and cTnI release), our results, detailed below, show that IPC reduces infarct size in all 3 species, that its cardioprotective effects are reproducible between the 2 centers for each species, and that the measurements of myocardial injury in each species and in each group are also reproducible between 2 centers.
Preliminary Studies
In the initial iterations of the mouse model, the data (not shown) indicated that infarct size reduction in each laboratory was, indeed, significant in the IPC group; however, secondary end points, such as age and body weight, were also significantly different between the 2 centers. Although both centers used the same models, there were subtle differences in interpretation and execution that became apparent and required reconciliation for subsequent studies. Accordingly, we engaged in multiple conference calls and site visits to identify differences in protocol performance. These efforts required scrupulous auditing of detailed laboratory practices, animal care facility procedures (eg, specific diet used), coordination between the centers, and the most Herculean task of all: having 2 laboratories strictly adhere to a continuously refined set of practices. The initial phase of CAESAR's operation was precisely designed to address such minor procedural differences, and such a sweeping evaluation was also performed for the rabbit and pig models. Establishing consistent protocols, with attention to the minutest details, represented a major hurdle to reproducibility in the early stages of CAESAR and was an issue for all 3 models (mouse, rabbit, and pig). The experience accumulated in these preliminary studies demonstrates not only how difficult it is for different laboratories to adhere to the same protocol but also how important even subtle differences in execution can be in shaping the final outcome.
To illustrate the types of differences encountered, we provide examples of changes that were made in the early phases of CAESAR. For example, in the initial pilot studies in the mouse model, the RR normalized to the LV (RR/LV) was significantly larger at the Emory Center than at the University of Louisville Center because of slightly different practices in reporting tissue weights. The centers subsequently normalized the procedural differences to achieve similar RR/LV; however, other differences were ascribed to small, seemingly inconsequential differences at each site. For example, in the pilot studies, body weights were slightly but significantly greater at Emory than at University of Louisville, despite identical diets and despite using the same mouse vendor. Such differences can be accounted for (as is done in clinical trials) because there was no statistically attributable influence of body weight on infarct size in the present study, this particular issue was moot. Table 1 contains the combined data from the 2 centers (after reconciliation of differences in the pilot stage) with respect to group assignment. Thirty-two mice were enrolled in the control group; 7 were excluded. Twenty-five mice were enrolled in the IPC group; 3 were excluded. There were no significant differences between the control and IPC groups with respect to the end points of exclusions, age, body weight, or RR. At 5 minutes of occlusion, body temperature was significantly lower (≈0.2°C) in the IPC group than in controls. Although such a difference is statistically significant, it is difficult to assign physiological significance to such a transient, nominal difference; there were no other significant differences in body temperature. Heart rate was significantly lower at 5 and 15 minutes of occlusion and at 15 minutes of reperfusion, in the IPC group; however, post hoc analysis to determine whether heart rate was associated with infarct size indicated that no such relationship existed in this study, thereby ruling out heart rate differences as an explanation for differences in infarct size. Most importantly, the primary end points of infarct size and cTnI release ( Figure 3) were significantly reduced in the IPC group when compared with that in the controls. Thus, CAESAR February 13, 2015 was able to demonstrate the cardioprotective effects of the most widely reproduced intervention for infarct size reduction successfully.
Results in the Mouse Model
Online Table I lists the summarized values for all of the assessed end points in mice; the data are segregated by the center. Overall, these data indicate internal consistency within each center (ie, few statistically significant differences between the 2 groups, within a center). Moreover, the experiences of the 2 centers were similar, inasmuch as there were few differences between the 2 centers. These data indicate that the Mouse Centers can collectively demonstrate infarct size reduction and consistently achieve similar results in an anesthetized mouse model of myocardial ischemia/reperfusion injury. Table 2 contains the combined data from the 2 centers with respect to group assignment in the rabbit model. Sixteen rabbits were enrolled in the control group; 4 were excluded. Thirteen rabbits were enrolled in the IPC group; 2 were excluded. There were no significant differences between the control and IPC groups with respect to number of exclusions, age, body weight, number of defibrillations, heart rate (at any time), or RR. Because the rabbit model is a conscious model of myocardial infarction, body temperature was not measured. Most importantly, the primary end points of infarct size and cTnI release ( Figure 4) were significantly reduced in the IPC group when compared with that in the control. Thus, CAESAR was able to demonstrate the infarct-sparing actions of the most widely reproduced intervention for infarct size reduction in a conscious rabbit model of myocardial ischemia/reperfusion injury successfully.
Results in the Rabbit Model
It is important to note that, similar to our experience in the mouse model, the pilot studies (not shown) in the rabbit model indicated that IPC significantly reduced infarct size in each center; however, several secondary end points, such as age and body weight, were also significantly different between the 2 centers. To achieve reproducibility between the 2 centers, University of Louisville and Virginia Commonwealth University scrupulously evaluated their detailed protocols and identified several small differences. The result of this audit led the 2 centers to switch to the same vendor for the rabbits and better coordinate the age by synchronizing their centers' animal orders. Because the rabbit model involved survival surgery (for the instrumentation), there were also small differences in the type and route of analgesia that, although unlikely to contribute to center differences, were reconciled through cooperation of the centers' respective Institutional Animal Care and Use Committee. Once the center differences were addressed, the models were used for the IPC study and the data are reported in Table 2  and Online Table II. Online Table II lists the summarized values for all of the assessed end points in rabbits; the data are segregated by center. Overall, these data indicate internal consistency within each center (ie, few statistically significant differences between the 2 groups, within a center). Moreover, the experiences of the 2 centers were similar, inasmuch as there were few differences between the centers. These data indicate that the rabbit centers can demonstrate the infarct-sparing effect of IPC and consistently achieve similar results. Table 3 contains the combined data from the 2 centers with respect to group assignment in the pig model. Fifteen pigs were enrolled in the control group; 2 were excluded. Nineteen pigs were enrolled in the IPC group; 6 were excluded. There were no significant differences between the control and IPC groups with respect to number of exclusions, age, body weight, number of defibrillations, heart rate (at any time), mean arterial pressure, RR, or regional myocardial blood flow. Most importantly, the primary end points of infarct size and cTnI release ( Figure 5 ) were significantly reduced in the IPC group when compared with that in the control. Thus, CAESAR was able to demonstrate the cardioprotective effects of the most widely reproduced intervention The number of observations for baseline cTnl measurements is 17 for control and 14 for IPC. CTnI indicates cardiac troponin I; HR, heart rate; IPC, ischemic preconditioning; LV, left ventricle/ventricular; and RR, region at risk.
Results in the Pig Model
for infarct size reduction in the pig model of myocardial ischemia/reperfusion injury successfully.
Online Table III lists the summarized values of all of the assessed end points in pigs; the data are segregated by the center. Overall, these data indicate internal consistency within each center (ie, few statistically significant differences between the 2 groups, within a center). Moreover, the experiences of the 2 centers were highly similar, inasmuch as there were few differences between the centers. These data indicate that the pig centers can demonstrate the infarct-sparing effect of IPC and consistently achieve similar results.
Discussion
The purpose of CAESAR is to verify, in a rigorous manner, the efficacy of promising therapies for which there is already some evidence of efficacy. This work is essential if we hope to break the abysmal chain of failures in translating preclinical successes into clinical practice. 5 CAESAR represents a major paradigm shift and an innovative effort to achieve such a goal. It is predicated on the premises that (1) the translational failures that have plagued the field of cardioprotection for the past 40 years have been caused by the fact that most positive preclinical studies have not been reproducible and have not been conducted with sufficient rigor and (2) therapies that prove reproducibly effective in rigorous preclinical models will be more likely to be effective in patients. In our view, the role of CAESAR is to identify not only promising (ie, successful) infarct-sparing agents, but also, equally importantly, cardioprotective agents that are not likely to be efficacious in humans, thereby sparing millions of dollars and years of work involved in performing clinical trials of agents that do not withstand CAESAR's test.
However, before CAESAR can be used to evaluate potentially cardioprotective therapies, it is necessary to demonstrate that it is able to detect infarct size limitation. This positive control is essential to validate any negative results that may be encountered in subsequent studies. IPC was selected as the initial test for CAESAR because it is the most reproducible infarct-sparing intervention discovered to date. The first phase of CAESAR provided opportunities for protocol refinement, demonstrated the ability of the consortium to detect an effective intervention, and introduced the CAESAR investigators to the concept of multicenter integration of a single study, a common concept among clinician-investigators but a revolutionary concept for laboratory scientists.
These objectives were successfully achieved. The collective results of CAESAR's 6 surgical centers indicate that IPC significantly reduced infarct size in all 3 animal models used; furthermore, the reduction in infarct size by IPC, as well as the values of infarct size in the control and IPC groups, was consistent between the 2 centers involved in each model. Thus, the infrastructure that we have developed (1) can operate effectively in accordance with our goals of investigative rigor and reproducibility between centers and (2) can demonstrate cardioprotection. These findings are of paramount importance , and left ventricular (LV) areas were determined with a dual-stain technique as described in the Methods section of this article. There was no difference in RR/LV between control and IPC; however, IPC significantly reduced Inf/RR. B, To determine cardiac damage with a different method, plasma levels of cardiac troponin I (cTnI) were determined with a mouse-specific commercial ELISA kit. IPC significantly reduced cTnI levels at 2 hours of reperfusion in mice. Results are expressed as mean±SD. *P<0.05. February 13, 2015 because they lay the necessary foundation for subsequent studies of novel infarct-sparing therapies by CAESAR.
Of even greater importance, however, is the fact that the present work provides information that could potentially transform basic research on cardioprotection: that is, a detailed description of state-of-the-art methodology that any laboratory, even outside of a network, can adopt to measure infarct size in a manner that is rigorous, accurate, and reproducible. In addition to the principles of randomization, investigator blinding, a priori sample size determination and exclusion criteria, and appropriate statistical analyses embodied by CAESAR, we provide herein detailed protocols ("CAESAR protocols") for 3 major models of ischemiareperfusion injury: the mouse, rabbit, and pig models. Each of these protocols is supported by a large body of previous work 22, 31, [36] [37] [38] and is the result of extensive discussions among centers and validation studies in the preliminary phase of CAESAR. Our results demonstrate that adherence to these protocols results in accurate and reproducible measurements of infarct size. Accordingly, these detailed protocols should be useful to other investigators who are engaged in studies of infarct size reduction. The establishment of a multicenter, multispecies, preclinical consortium for the rigorous assessment of cardioprotective interventions described herein is truly a revolutionary approach, as this has never been done before in studies of infarct size limitation. Others have used different protocols at 3 sites in a single species to evaluate a single therapy. 39 CAESAR is unique also because it constitutes a public resource. The enormity of our goal required a relatively large operational structure (Figure 1 ), which we envisioned as operating in a manner analogous to a multicenter clinical trial. Investigators at 4 universities (currently: University of Louisville, LSUHSC-New Orleans [previously Emory University], Johns Hopkins University, and Virginia Commonwealth University) constitute the Consortium Operations Committee (COC), which functions as a Steering/ Executive Committee for CAESAR. In addition, most of the COC members lead Surgical Centers and Cores and thus work on protocol implementation (Figure 1 ). Because the National Institutes of Health U24 funding mechanism (which supports CAESAR) represents a bona fide partnership between the National Heart, Lung, and Blood Institute and the CAESAR investigators, there are 2 nonvoting members of the COC who represent the National Heart, Lung, and Blood Institute (currently: Dr Frank Evans and Ms Lynn Rundhaugen; previously: Dr Isabella Liang). These scientists provide important feedback from the National Heart, Lung, and Blood Institute, make suggestions on protocol refinement and participate in COC conference calls, which occur on a monthly basis or more frequently should specific issues arise.
Whereas a clinical trial has a Data Safety Monitoring Board, CAESAR has a PRMC, which consists of a nonvoting Executive Secretary and 4 voting members (Figure 1 ). During CAESAR's development, the PRMC provided critical feedback that improved the protocols at the centers and cores. Now that CAESAR has been validated and is actively testing candidate agents (see www.nihcaesar.org for current status), the PRMC's primary functions are to approve the use of putative cardioprotective agents proposed by scientists and private companies outside of the COC and to evaluate the blinded data to determine whether ongoing studies should stop or continue. Throughout this process, the 2 members of the DCC (currently: Drs Jones and Kong) are the only CAESAR investigators who have access to group assignments and information on summary data. All other CAESAR investigators will have seen, at most, only aggregate data (all groups combined into 1 group), which provide only general , and left ventricular (LV) areas were determined with a dual-stain technique as described in the Methods section of this article. There was no difference in RR/LV between control and IPC; however, IPC significantly reduced Inf/RR. B, To determine cardiac damage with a different method, plasma levels of cardiac troponin I (cTnI) were determined with a rabbit-specific commercial ELISA kit. IPC significantly reduced cTnI levels early during reperfusion. C, IPC also significantly reduced total cTnI release, as estimated by the area under the curve. Results are expressed as mean±SD. *P<0.05. February 13, 2015 insight into overall protocol adherence (based on animal age, body weight, or other biometric parameters). Thus, the investigators generating the raw data (or data derived therefrom) are truly blinded throughout the entire process. Once reported to the PRMC, a study continues (if the report was an interim analysis) or is closed. When a study is closed and the minutes of the PRMC conference call are made official by the National Heart, Lung, and Blood Institute, then, and only then, are the CAESAR investigators (including the overall PI, Dr Bolli) notified of the results. The next step is for the CAESAR investigators to disseminate the findings via abstract presentations at conferences and via full-length, peerreviewed articles.
We found the development of CAESAR to be challenging. Converting several fiercely independent investigators into a cooperative and uniform team has rarely been achieved in basic research. In addition, achieving harmony among multiple Institutional Animal Care and Use Committees for the implementation of consistent protocols is difficult and time-intensive. Furthermore, such a multiinstitutional and complex infrastructure requires a much higher administrative obligation, as illustrated in Figure 1 . The challenge of developing CAESAR was not less than that inherent in launching a new multicenter clinical trial. Nevertheless, we think that such an infrastructure is indispensable to move the field of cardioprotection forward beyond its current impasse.
Although in this study of IPC all centers and cores (with the exception of the DCC) were blinded to the results until the study was completed, IPC makes it virtually impossible to blind investigators to group allocation. In subsequent CAESAR studies, 40 ,41 the most critical difference has been that neither the individuals performing the experiments nor those conducting subsequent analyses have had any knowledge of group assignment. Therefore, there are 2 differences between this IPC study and all subsequent CAESAR studies. First, although in the present study, the pathologist was blinded to group assignment, the surgeons were not blinded to group assignment. Second, IPC is, by definition, an antecedent intervention; in subsequent studies, drugs tested in CAESAR have not been administered until late in ischemia. Such a design is motivated by our desire to bolster the translational potential of CAESAR's efforts.
An important result of this study is that, in the absence of any intervention, results varied if the diet, age (size), or source of the animal were different. This finding has major implications for studies of infarct size because it reveals heretofore unappreciated confounding variables that may affect the outcome of many investigations published in the literature, thereby requiring rigorous standardization of these conditions in additional studies. This finding emphasizes the importance of using a structure like CAESAR to achieve reproducible results and the importance of paying attention to even minute differences in operations among different laboratories.
Despite CAESAR's unique strengths in terms of protocol rigor, statistical power, blinding, and randomization, certain limitations should be mentioned. Like in nearly all preclinical studies of infarct size reduction, CAESAR animals are young and healthy and, thus, devoid of risk factors. This aspect of CAESAR (and most preclinical studies of infarct size limitation to date) creates the possibility that some interventions may succeed in CAESAR, yet fail in humans because of the high prevalence of risk factors, comorbidities, and concurrent polypharmacy. Future iterations of CAESAR should include appropriate risk factors in the models. 13, 14 In addition, the ability of CAESAR to predict what will eventually succeed or fail in patients has no positive control. That is, because no drug is approved to limit infarct size in patients, there is nothing we can test in CAESAR to demonstrate that CAESAR can predict drugs that will be effective in patients (indeed, the reason for CAESAR's existence is that there is no intervention that has been accepted to limit infarct size in humans).
In summary, infarct size limitation remains a major unmet medical need. Despite enormous investments by National Institutes of Health and private entities, and despite innumerable preclinical and clinical attempts, to date there is no drug that can be used in patients to limit infarct size. This colossal failure can be ascribed mainly to methodological limitations (ie, to insufficient rigor in the studies conducted heretofore). CAESAR is a novel, revolutionary paradigm shift in cardioprotection, which provides a mechanism for assessing cardioprotective interventions with a level of rigor analogous to that used in multicenter randomized clinical trials. The present study demonstrates that CAESAR is operational, generates reproducible results, and can identify cardioprotection. Our experience also offers insights into how to build an effective and coordinated preclinical network. Most importantly, we provide here the CAESAR protocols-state-of-the-art, detailed protocols for measuring infarct size in mice, rabbits, and pigs in a manner that is rigorous, accurate, and reproducible; other investigators can adopt these protocols in their own laboratories. CAESAR is a public resource available to external investigators (www.nihcaesar.org). The CAESAR investigators look forward to continued engagement with the cardiovascular community in terms of proposal submissions and constructive feedback.
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What Is Known?
• After decades of effort and investment of hundreds of millions of dollars, there are still no drugs generally accepted to reduce infarct size in patients.
• Many candidate drugs have arisen from preclinical studies of varying quality and reproducibility.
• Because most laboratory studies of myocardial ischemia-reperfusion injury are not standardized and often poorly controlled, we need to develop a better approach to identify infarct-sparing drugs.
What New Information Does This Article Contribute?
• This study provides detailed experimental protocols for the rigorous assessment of myocardial infarct size in three commonly used laboratory species.
• This article provides a roadmap for applying a clinical trial-like approach to preclinical studies of infarct-sparing drugs, which could easily be adopted in other areas of cardiovascular research.
Despite 4 decades of intense effort and substantial financial investment, the cardioprotection field has failed to deliver a single drug that is generally accepted to reduce myocardial infarct size in patients. The purpose of Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR) is to verify, in a rigorous manner, the efficacy of promising therapies. This work is essential if we hope to break the abysmal chain of failures in translating preclinical successes into clinical practice. Our goal was to develop a multicenter randomized controlled trial-like infrastructure to conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies. CAESAR represents a major paradigm shift and an innovative effort to achieve such a goal. It is predicated on the premises that (1) the translational failures that have plagued the field of cardioprotection for the past 40 years have been caused by the fact that most positive preclinical studies have not been reproducible and have not been conducted with sufficient rigor and (2) therapies that prove reproducibly effective in rigorous preclinical models will be more likely to be effective in patients. CAESAR is operational, generates reproducible results, can detect cardioprotection, and provides a mechanism for assessing potential infarct-sparing therapies with a level of rigor analogous to multicenter randomized controlled trials.
Novelty and Significance
